Dronedarone in High-Risk Permanent Atrial Fibrillation

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:DiVA.org:uu-163774" > Dronedarone in High...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Connolly, Stuart J (author)

Dronedarone in High-Risk Permanent Atrial Fibrillation

Article/chapterEnglish2011

Publisher, publication year, extent ...

2011
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:uu-163774
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-163774URI
https://doi.org/10.1056/NEJMoa1109867DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Background Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular anti-arrhythmic effects. We hypothesized that dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation. Methods We assigned patients who were at least 65 years of age with at least a 6-month history of permanent atrial fibrillation and risk factors for major vascular events to receive dronedarone or placebo. The first coprimary outcome was stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes. The second coprimary outcome was unplanned hospitalization for a cardiovascular cause or death. Results After the enrollment of 3236 patients, the study was stopped for safety reasons. The first coprimary outcome occurred in 43 patients receiving dronedarone and 19 receiving placebo (hazard ratio, 2.29; 95% confidence interval [CI], 1.34 to 3.94; P=0.002). There were 21 deaths from cardiovascular causes in the dronedarone group and 10 in the placebo group (hazard ratio, 2.11; 95% CI, 1.00 to 4.49; P=0.046), including death from arrhythmia in 13 patients and 4 patients, respectively (hazard ratio, 3.26; 95% CI, 1.06 to 10.00; P=0.03). Stroke occurred in 23 patients in the dronedarone group and 10 in the placebo group (hazard ratio, 2.32; 95% CI, 1.11 to 4.88; P=0.02). Hospitalization for heart failure occurred in 43 patients in the dronedarone group and 24 in the placebo group (hazard ratio, 1.81; 95% CI, 1.10 to 2.99; P=0.02). Conclusions Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events. Our data show that this drug should not be used in such patients.

Added entries (persons, corporate bodies, meetings, titles ...)

Camm, A John (author)
Halperin, Jonathan L (author)
Joyner, Campbell (author)
Alings, Marco (author)
Amerena, John (author)
Atar, Dan (author)
Avezum, Alvaro (author)
Blomström, PerUppsala universitet,Institutionen för medicinska vetenskaper,Kardiologi elektrokardiologi(Swepub:uu)perbloms (author)
Borggrefe, Martin (author)
Budaj, Andrzej (author)
Chen, Shih-Ann (author)
Ching, Chi Keong (author)
Commerford, Patrick (author)
Dans, Antonio (author)
Davy, Jean-Marc (author)
Delacrétaz, Etienne (author)
Di Pasquale, Giuseppe (author)
Diaz, Rafael (author)
Dorian, Paul (author)
Flaker, Greg (author)
Golitsyn, Sergey (author)
Gonzalez-Hermosillo, Antonio (author)
Granger, Christopher B (author)
Heidbüchel, Hein (author)
Kautzner, Josef (author)
Kim, June Soo (author)
Lanas, Fernando (author)
Lewis, Basil S (author)
Merino, Jose L (author)
Morillo, Carlos (author)
Murin, Jan (author)
Narasimhan, Calambur (author)
Paolasso, Ernesto (author)
Parkhomenko, Alexander (author)
Peters, Nicholas S (author)
Sim, Kui-Hian (author)
Stiles, Martin K (author)
Tanomsup, Supachai (author)
Toivonen, Lauri (author)
Tomcsányi, János (author)
Torp-Pedersen, Christian (author)
Tse, Hung-Fat (author)
Vardas, Panos (author)
Vinereanu, Dragos (author)
Xavier, Denis (author)
Zhu, Jun (author)
Zhu, Jun-Ren (author)
Baret-Cormel, Lydie (author)
Weinling, Estelle (author)
Staiger, Christoph (author)
Yusuf, Salim (author)
Chrolavicius, Susan (author)
Afzal, Rizwan (author)
Hohnloser, Stefan H (author)
Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Related titles

In:New England Journal of Medicine365:24, s. 2268-22760028-47931533-4406

Internet link

Find in a library

New England Journal of Medicine (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Connolly, Stuart ...; Camm, A John; Halperin, Jonath ...; Joyner, Campbell; Alings, Marco; Amerena, John; show more...; Atar, Dan; Avezum, Alvaro; Blomström, Per; Borggrefe, Marti ...; Budaj, Andrzej; Chen, Shih-Ann; Ching, Chi Keong; Commerford, Patr ...; Dans, Antonio; Davy, Jean-Marc; Delacrétaz, Etie ...; Di Pasquale, Giu ...; Diaz, Rafael; Dorian, Paul; Flaker, Greg; Golitsyn, Sergey; Gonzalez-Hermosi ...; Granger, Christo ...; Heidbüchel, Hein; Kautzner, Josef; Kim, June Soo; Lanas, Fernando; Lewis, Basil S; Merino, Jose L; Morillo, Carlos; Murin, Jan; Narasimhan, Cala ...; Paolasso, Ernest ...; Parkhomenko, Ale ...; Peters, Nicholas ...; Sim, Kui-Hian; Stiles, Martin K; Tanomsup, Supach ...; Toivonen, Lauri; Tomcsányi, János; Torp-Pedersen, C ...; Tse, Hung-Fat; Vardas, Panos; Vinereanu, Drago ...; Xavier, Denis; Zhu, Jun; Zhu, Jun-Ren; Baret-Cormel, Ly ...; Weinling, Estell ...; Staiger, Christo ...; Yusuf, Salim; Chrolavicius, Su ...; Afzal, Rizwan; Hohnloser, Stefa ...; show less...

Articles in the publication: New England Jour ...

By the university: Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se